Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume – Time to Buy?

Genmab A/S (NASDAQ:GMAB) shares saw unusually-strong trading volume on Monday . Approximately 3,133,669 shares changed hands during mid-day trading, an increase of 259% from the previous session’s volume of 873,369 shares.The stock last traded at $22.40 and had previously closed at $24.14.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Stock Performance

The business has a 50-day simple moving average of $21.28 and a two-hundred day simple moving average of $22.62. The company has a market capitalization of $14.55 billion, a price-to-earnings ratio of 12.64, a PEG ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Employees Retirement System of Texas acquired a new stake in Genmab A/S in the fourth quarter valued at about $1,648,000. Mackenzie Financial Corp acquired a new position in Genmab A/S during the 4th quarter worth approximately $689,000. GTS Securities LLC purchased a new position in shares of Genmab A/S during the 4th quarter worth approximately $1,552,000. Vise Technologies Inc. lifted its holdings in shares of Genmab A/S by 41.7% in the 4th quarter. Vise Technologies Inc. now owns 12,892 shares of the company’s stock valued at $269,000 after buying an additional 3,794 shares during the period. Finally, Voloridge Investment Management LLC boosted its stake in shares of Genmab A/S by 102.4% in the fourth quarter. Voloridge Investment Management LLC now owns 1,110,191 shares of the company’s stock valued at $23,170,000 after buying an additional 561,767 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.